InvestorsHub Logo
Followers 231
Posts 34993
Boards Moderated 1
Alias Born 11/19/2003

Re: None

Friday, 02/15/2019 2:25:58 PM

Friday, February 15, 2019 2:25:58 PM

Post# of 5907
Sat Feb 16, 2019 ASCO presentation Phase 3 Tivo-3

study of tivozanib vs sorafenib in refractory advanced or metastatic renal cell carcinoma will be presented tomorrow at the 2019 ASCO GU Symposium in San Francisco. Here’s the link to the abstract:

https://meetinglibrary.asco.org/record/170192/abstract